Compare QNC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNC | CMPX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | Canada | United States |
| Employees | 5 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.7M | 371.0M |
| IPO Year | 2026 | 2020 |
| Metric | QNC | CMPX |
|---|---|---|
| Price | $3.17 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 1.2M | ★ 3.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $934.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.90 | $1.61 |
| 52 Week High | $3.59 | $6.88 |
| Indicator | QNC | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 43.06 |
| Support Level | $2.63 | $1.88 |
| Resistance Level | $3.51 | $2.47 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 51.15 | 62.71 |
Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.